The Role of Neuroactive Steroids in Stress, Drug craving and Drug Use in Alcohol Use Disorders
Addictive Behaviors | Alcohol Addiction | Mental Health & Behavioral Research
What is the purpose of this trial?
The proposed study will enroll 90 treatment seeking individuals with alcohol use disorder (45 Men; 45 Women), who will be randomized to receive either 300mg pregnenolone (n=30), 500mg pregnenolone (n=30) or placebo (n=30) in a double blind manner, for 8 weeks. Throughout the trial, subjects will visit the Yale Stress Center for twice-weekly appointments to assess alcohol use outcomes in person and also via daily smartphone monitoring. In week 2, participants will be exposed to 3 laboratory sessions of guided imagery conditions (stress, drug cue and neutral); one per day across consecutive days in a counterbalanced and random order.
- Ages18 years - 60 years
- Trial withYale University School of Medicine
- Start Date10/21/2018
- End Date07/30/2021
- Last Updated03/13/2020
- Study HIC#1608018179